Increased reactive oxygen species (ROS); oxidative stress induction |
Decreased population growth rate/Decreased population size |
8 |
MIE in AOP 444*; KE in AOP 386*, AOP 387*, AOP 396*, AOP 299*, AOP 311*, AOP 325*, AOP 326* |
Lung fibrosis/Lung cancer/Decreased lung function/Dysfunction of the respiratory system |
7 |
MIE in AOP 481*; KE in AOP 382*, AOP 319*, AOP 303*, AOP 416*, AOP 451*, AOP 418* |
Liver fibrosis/Cholestasis/Steatohepatitis/Liver injury |
5 |
KE in AOP 383*, AOP 27*, AOP 213 (open for adoption), AOP 273*, AOP 494* |
Breast cancer |
2 |
MIE in AOP 294*; KE in AOP 293* |
Increased mortality |
7 |
MIE in AOP 327*, AOP 328*, AOP 329*, AOP 330*, AOP 186*; KE in AOP 377*, AOP 413 (open for citation & comment) |
Reproductive failure/Decreased fertility/Decreased reproductive success/Impaired fertility |
4 |
KE in AOP 207*, AOP 476*, AOP 473*, AOP 492* |
Treatment-resistant gastric cancer |
1 |
MIE in AOP 298 (under review) |
Decreased cognitive function |
1 |
MIE in AOP 488* |
Inflammatory events in light-exposed tissues |
1 |
MIE in AOP 282 (under review) |
Insulin resistance |
2 |
KE in AOP 457*, AOP 497* |
Chronic kidney disease |
1 |
KE in AOP 384* |
Apoptotic cell death |
1 |
MIE in AOP 423* |
Increased oxidative damage |
1 |
KE in AOP 26 (open for adoption) |
Increased mesotheliomas |
1 |
KE in AOP 409* |
Acute myeloid leukaemia |
1 |
KE in AOP 432* |
DNA damage/DNA strand breaks |
Decreased population growth rate/Decreased population size/Decreased population trajectory |
6 |
KE in AOP 388*, AOP 444*, AOP 216*, AOP 238*, AOP 396*, AOP 435* |
Lung cancer |
5 |
KE in AOP 303*, AOP 451*, AOP 416*, AOP 417*, AOP 272 (Approved) |
Breast cancer |
4 |
MIE in AOP 443*, AOP 293*, AOP 294* KE in AOP 200 (open for adoption) |
Decreased fertility/Reduced sperm count |
2 |
KE in AOP 476*, AOP 322* |
Increased mesotheliomas |
1 |
KE in AOP 409* |
Acute myeloid leukaemia |
1 |
KE in AOP 432* |
Microcephaly |
1 |
KE in AOP 441* |
Apoptotic cell death |
1 |
KE in AOP 423* |
Increased chromosomal aberrations |
1 |
KE in AOP 296 (endorsed) |
Cataracts |
1 |
KE in AOP 478 (open for citation & comment) |
Learning and memory impairment |
1 |
KE in AOP 483 (open for citations & comments) |
Vascular remodelling |
1 |
KE in AOP 470 (open for citations & comments) |
Increased lipid peroxidation |
Increased mortality |
2 |
KE in AOP 413 (open for citation & comment), AOP 329* |
Impaired fertility |
1 |
KE in AOP 492* |
Apoptosis |
Decreased population growth |
3 |
KE in AOP 340*, AOP 341*, AOP 444* |
Decreased fertility/Reproductive failure/Decreased reproduction |
4 |
KE in AOP 70*, AOP 71*, AOP 207*, AOP 476* |
Orofacial cleating |
2 |
KE in AOP 460*, AOP 491* |
Breast cancer |
2 |
KE in AOP 200 (open for adoption), AOP 439* |
Decreased lung function/Chronic obstructive pulmonary disease |
2 |
KE in AOP 419*, AOP 452* |
Prostate cancer |
1 |
KE in AOP 495* |
Apoptosis/Necrosis |
1 |
AO in AOP 205 (open for comment) |
Testicular atrophy |
1 |
KE in AOP 212 (endorsed) |
Liver injury |
1 |
KE in AOP 285* |
Thyroid hormone interference |
1 |
KE in AOP 393* |
Neurodegeneration |
1 |
KE in AOP 260* |
Kidney failure |
1 |
KE in AOP 447* |
Lysosomal disruption |
Kidney toxicity |
1 |
KE in AOP 257* |
Liver fibrosis |
1 |
KE in AOP 144 (under review) |
Decreased locomotor activity |
Decreased population growth rate |
1 |
KE in AOP 218 (not under active development) |
Decrease in body weight |
Decreased body weight |
1 |
AO in AOP 6 (endorsed) |
Glutathione depletion |
Impaired fertility |
1 |
KE in AOP 492 * |
Inflammation/Neuroinflammation |
Learning and memory impairment |
4 |
KE in AOP 12 (endorsed), AOP 17 (endorsed), AOP 48 (endorsed), AOP 490* |
Parkinsonian motor deficits |
2 |
KE in AOP 3 (endorsed), AOP 464* |
Lung fibrosis/Bronchiolitis obliterans/Chronic obstructive pulmonary disease |
3 |
KE in AOP 206*, AOP 280*, AOP 452* |
Cholestasis/Immune-mediated hepatitis/Increased liver steatosis |
2 |
KE in AOP 413*, AOP 362* MIE in AOP 62* |
Increase, papillomas/carcinomas |
2 |
KE in AOP 114*, AOP 115* |
Psoriatic skin disease |
1 |
KE in AOP 313* |
Increased mortality |
1 |
KE in AOP 377* |
Hyperinflammation |
1 |
AO in AOP 392* |
Memory Loss |
1 |
KE in AOP 429* |
Kidney failure |
1 |
KE in AOP 447* |
Metabolically unhealthy obesity |
1 |
KE in AOP 493* |
Increased mesotheliomas |
1 |
KE in AOP 171* |
Breast cancer |
1 |
KE in AOP 439* |
Pulmonary inflammation |
Chronic obstructive pulmonary disease |
1 |
KE in AOP 452* |
Respiratory dysfunction |
1 |
KE in AOP 481* |
Increased mesotheliomas |
1 |
KE in AOP 409* |
Increased mortality |
1 |
KE in AOP 377* |
Hypersensitivity response |
1 |
KE in AOP 39* |
Atherosclerosis |
1 |
KE in AOP 237* |
Increased neutrophil activation |
Increased thrombo-inflammation |
1 |
KE in AOP 412* |
Mitochondrial dysfunction |
Death/Failure, Colony |
6 |
KE in AOP 77 (open for comment), AOP 78 (open for comment), AOP 79 (open for comment), AOP 80 (open for comment), AOP 87 (open for comment), AOP 178* |
Decreased population growth rate |
3 |
MIE in AOP 326*, AOP 325*, AOP 324* |
Heart failure/Increased mortality |
3 |
KE in AOP 479*, AOP 480*, AOP 377* |
Kidney failure/Kidney toxicity |
2 |
KE in AOP 447*, AOP 437* |
Liver fibrosis/Liver injury |
2 |
KE in AOP 144 (under review), AOP 273* |
Learning and memory impairment |
1 |
KE in AOP 48 (endorsed) |
Parkinsonian motor deficits |
1 |
KE in AOP 3 (endorsed) |
Breast cancer |
1 |
KE in AOP 200 (open for adoption) |
Apoptotic cell death |
1 |
KE in AOP 423* |
Impaired IL-1R signalling |
T-cell-dependent antibody response impairment |
1 |
MIE in AOP 277 (under review) |
Energy reserves depletion/Decreased fatty acid beta-oxidation |
Decreased population growth rate |
1 |
KE in AOP 97* |
Decreased body weight |
1 |
KE in AOP 6 (endorsed) |
Blocked enzyme production (inhibition of aromatase/calcineurin activity) |
T-cell-dependent antibody response impairment |
1 |
KE in AOP 154 (endorsed) |
Metastasis, Breast Cancer |
1 |
KE in AOP 443* |
Decreased fertility |
1 |
MIE in AOP 153* |
Decreased fecundity/fertility |
Decreased fecundity/Decreased population growth rate/Decreased fertility |
13 |
AO in AOP 73*, AOP 126*, AOP 345*, AOP 476*, AOP 64*, AOP 66*, AOP 67*, AOP 68*, AOP 70*, AOP 71*, AOP 74*, AOP 153* KE in AOP 444* |
Oxidation of iron in haemoglobin |
Cyanosis |
1 |
MIE in AOP 31* |
Endoplasmic reticulum stress |
Non-alcoholic fatty liver disease/Tumorigenesis |
1 |
KE in AOP 454* |
Parkinsonian motor deficits |
1 |
KE in AOP 464* |
Decreased cholesterol/altered cholesterol metabolism |
Impaired fertility |
2 |
KE in AOP 51*, AOP 18 (under review) |
Decreased sperm quantity and/or quality in the adult testis |
1 |
MIE/KE in AOP 69* |
Decreased cognitive function |
1 |
KE in AOP 487* |
Altered lipid metabolism |
Steatohepatitis |
1 |
KE in AOP 401* |
Pancreatic acinar tumours |
1 |
KE in AOP 166* |
Metabolic syndrome/stress |
Metabolic syndrome/Insulin resistance |
1 |
AO in AOP 497* |
Death/Failure, Colony |
1 |
KE in AOP 81 (open for comment) |
Increased blood CCK level (satiety) |
Pancreatic acinar cell tumours |
1 |
KE in AOP 316* |
Cell injury |
Learning and memory impairment |
5 |
KE in AOP 48 (endorsed), AOP 13 (endorsed), AOP 12 (endorsed), AOP 17 (endorsed), AOP 490* |
Liver fibrosis/Liver injury/ |
5 |
KE in AOP 38 (endorsed), AOP 144 (under review), AOP 278*, AOP 273*, AOP 494* |
Decreased growth |
3 |
KE in AOP 265*, AOP 264*, AOP 266* |
Heart failure/Increased mortality |
2 |
KE in AOP 479*, AOP 377* |
Neurodegeneration |
1 |
KE in AOP 281* |
Inhibition of digestive enzymatic activities (trypsin inhibition) |
Pancreatic acinar cell tumours |
1 |
MIE in AOP 316* |
Alteration in intestinal microbiota |
Gut dysbiosis |
1 |
KE in AOP 428* |
Decrease in gene expression related to liver |
Increased hepatocellular adenomas and carcinomas |
1 |
KE in AOP 107 (under review) |
Covalent protein binding |
Sensitisation of skin |
1 |
MIE in AOP 40 (endorsed) |
Increased allergic respiratory hypersensitivity response |
1 |
MIE in AOP 39* |
Meiotic spindle disorganisation |
Increased aneuploid offspring |
1 |
KE in AOP 106 (EAGMST under review) |
Increased mortality |
Increased mortality |
23 |
AO in AOP 16*, AOP 96*, AOP 104*, AOP 113*, AOP 160*, AOP 161*, AOP 138*, AOP 177*, AOP 186*, AOP 312*, AOP 155 (endorsed), AOP 156 (endorsed), AOP 157 (endorsed), AOP 158 (endorsed), AOP 159 (endorsed), AOP 363 (under review), AOP 377*, AOP 364 *, AOP 365 *, AOP 399 (open for citation & comment), AOP 413 (open for citation & comment), AOP 410 (open for citation & comment), AOP 450* |
Decreased population growth rate |
Decreased population growth rate |
54 |
AO in AOP 23 (endorsed), AOP 25 (endorsed), AOP 29*, AOP 30 (under review), AOP 100*, AOP 122(under development), AOP 123*, AOP 155 (endorsed), AOP 156 (endorsed), AOP 157 (endorsed), AOP 158 (endorsed), AOP 159 (endorsed), AOP 101*, AOP 102*, AOP 63*, AOP 103*, AOP 310*, AOP 16*, AOP 312*, AOP 334*, AOP 336*, AOP 337*, AOP 338*, AOP 339*, AOP 340*, AOP 341*, AOP 297*, AOP 346*, AOP 326*, AOP 325*, AOP 324*, AOP 363 (under review), AOP 348*, AOP 376 (open for citation & comment), AOP 386*, AOP 387*, AOP 388*, AOP 389*, AOP 364*, AOP 365*, AOP 399 (open for citation & comment), AOP 410 (open for citation & comment), AOP 216 *, AOP 238*, AOP 299*, AOP 311*, AOP 444*, AOP 138*, AOP 177*, AOP 97*, AOP 203*, AOP 218 (not under active development), AOP 219 (not under active development), AOP 323 (open for citation & comment) |